# Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents

Study · id `cardio:ct-nct01245374` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01245374](<https://clinicaltrials.gov/study/NCT01245374>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01245374

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

## Technical summary

Registry record NCT01245374. Non-randomized; no masking; primary purpose treatment. Start 2010-11 (registry gives no type); primary completion 2011-04 (actual). Results posted on 2012-06-25.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 103 participants (enrolled count; ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Start date: 2010-11 (registry gives no type) (ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Primary completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Completion: 2011-04 (actual) (ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Results first posted: 2012-06-25 (ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT01245374, source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01245374-2017-02-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
- Condition: Growth Hormone Disorder
- Condition: Growth Hormone Deficiency in Children
- Condition: Foetal Growth Problem
- Condition: Small for Gestational Age
- Condition: Genetic Disorder
- Condition: Turner Syndrome
- Condition: Chronic Kidney Disease
- Condition: Chronic Renal Insufficiency
- Condition: Delivery Systems
- Intervention (Device): Norditropin NordiFlex®
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: e6df7a5734c50dd34214e04fb1d90b624020f93c6cd424d6c10777dc18d181e8
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
